Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1383&sort=approved
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=approved", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1421&sort=approved", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=approved", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1382&sort=approved" }, "data": [ { "type": "Grant", "id": "12286", "attributes": { "award_id": "1U18HS029911-01", "title": "Advancing Long COVID Care in our Community through Access, Equity, and Collaboration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 22615, "first_name": "Brent", "last_name": "Sandmeyer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-30", "end_date": "2028-09-29", "award_amount": 962720, "principal_investigator": { "id": 28180, "first_name": "Abby Ling-Lee", "last_name": "Cheng", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28181, "first_name": "Jonas", "last_name": "Marschall", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28182, "first_name": "Amy", "last_name": "McQueen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Long COVID manifests differently for each person and can contribute to disabling, life-changing symptoms such as extreme fatigue, cognitive dysfunction, breathing difficulty, and autonomic dysfunction in people across the age spectrum, including in people who were previously healthy and in people who had minimal or no symptoms associated with acute COVID-19 infection. Multidisciplinary Long COVID clinics were a mainstay of patient support during the initial phases of the COVID-19 pandemic, but as the pandemic is shifting to a new phase, care models must also evolve in order to meet the complex medical, rehabilitative, and social needs of the continually growing number of people who are affected by Long COVID. The purpose of this project is to transform an existing, university-based Long COVID clinic into a broader Long COVID community network in order to expand equitable access to care, improve the patient care experience, and support primary care practitioners. This project will invest in two particularly underserved populations: 1) the Black community in St. Louis, Missouri, which is a historically mistreated population who continues to be marginalized by previously sanctioned segregation practices; and 2) rural communities across Missouri. Aim 1 is to expand equitable access to Long COVID care by: 1) building clinical capacity, and 2) removing structural barriers to care. This will be accomplished by: 1) hiring additional clinicians for the Long COVID Clinic in order to reduce wait times; and 2) removing patient requirements for clinic evaluation that disproportionately affect underserved populations. Aim 2 is to improve the Long COVID care experience by: 1) streamlining care that crosses multiple disciplines and physical care sites, and 2) supporting patients’ social needs. This will be accomplished by: 1) supporting a clinical case manager to directly assist patients with coordinating medical care and connecting with community resources, and 2) iteratively assessing and addressing referral challenges between clinics. Aim 3 is to support primary care teams as they care for patients with Long COVID by co-creating: 1) educational resources for PCPs, and 2) streamlined communication and referral pathways between PCPs and specialty clinicians. This will be accomplished by engaging multiple key stakeholders to: 1) develop multi- modality educational materials related to Long COVID patient assessment and management; 2) disseminate materials via culturally and logistically preferred approaches (including via established, trusted community intermediaries and via an established ECHO (Enhanced for Community Healthcare Outcomes) virtual educational infrastructure); and 3) refine existing handoff processes to minimize the administrative workload on PCP teams and facilitate their ability to meet patients’ needs. Continuous stakeholder input, comprehensive data tracking, and iterative needs assessments using mixed methods approaches will facilitate ongoing project evaluation and adaptation in order to respond to the community’s evolving needs.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12287", "attributes": { "award_id": "1R01GM152743-01", "title": "Collaborative Research: DMS/NIGMS 1: Identifiability investigation of Multi-scale Models of Infectious Diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 12060, "first_name": "Han", "last_name": "Nguyen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-27", "end_date": "2026-07-31", "award_amount": 183401, "principal_investigator": { "id": 28183, "first_name": "Stanca M.", "last_name": "Ciupe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 839, "ror": "", "name": "VIRGINIA POLYTECHNIC INST AND ST UNIV", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "The emergence and re-emergence of pathogens and their impact on society has reinforced the need for integration and synergy across scientific fields and biological scales in order to advance understanding, predicting, and responding to pathogen spread. Multi-scale mathematical models that consider the timing and length of individual infections when modeling transmission into the population can aid recommendations for optimal interventions. One shortcoming when evaluating data using multi-scale models comes from data scarcity in the expansion stages of the infection and transmission, the differences in data magnitude and frequency at each scale, together with the complexity of the models considered. To determine the source of combined biases in parameter estimation, we will use a combined empirical-theoretical approach for investigating structural and practical parameter identifiability of multi-scale models of infectious diseases that may inform optimal experimental design. The proposed research will facilitate a better understanding of the sources of uncertainty when fitting multi-scale models to multi-scale infectious disease data, with a focus on Usutu and SARS-CoV-2 viruses. By combining empirical and theoretical approaches we aim to determine structural and practical parameter identifiability of multi-scale models, to inform optimal experimental design, and to improve our ability to make predictions and suggest interventions. Our proposal will focus on three major mathematical challenges: (1) Developing methods for improving practical identifiability in within-host systems; (2) Use experimental data to inform development of transmission models; (3) Build a quantitative framework to predict parameter identifiability in multi-scale systems. The overarching goal of the proposed work is to integrate multi-scale mathematical model development and statistical models for data fitting with collection of longitudinal virus titers and probability of transmission data in order to decrease uncertainty and improve results reproducibility. This will ultimately improve our understanding of infection disease transmission and persistence.", "keywords": [ "2019-nCoV", "Animals", "Biological", "Birds", "Case Study", "Cessation of life", "Collaborations", "Collection", "Communicable Diseases", "Couples", "Culicidae", "Data", "Data Collection", "Data Set", "Databases", "Development", "Disease", "Disease Outbreaks", "Disease Progression", "Education", "Educational workshop", "Epidemiology", "Experimental Designs", "Frequencies", "Goals", "Grant", "Health", "Human", "Immune system", "Immunologic Markers", "Incidence", "Individual", "Infection", "Infectious Agent", "Interdisciplinary Study", "Intervention", "Investigation", "Length", "Link", "Mathematics", "Measurement", "Methods", "Modeling", "National Institute of General Medical Sciences", "Noise", "Parameter Estimation", "Pathogenesis", "Pharmacologic Substance", "Play", "Policies", "Population", "Probability", "Process", "Public Health", "Quarantine", "Recommendation", "Reporting", "Reproducibility", "Reproducibility of Results", "Research", "Role", "Sample Size", "Selection Bias", "Series", "Societies", "Source", "Specific qualifier value", "Statistical Models", "Students", "System", "Techniques", "Testing", "Time", "Uncertainty", "Viral", "Viral Load result", "Viral Markers", "Virus", "Virus Diseases", "Work", "age related", "curriculum development", "data exchange", "disease transmission", "improved", "infection rate", "infectious disease model", "influenza infection", "interest", "junior high school", "mathematical methods", "mathematical model", "model development", "multi-scale modeling", "multidisciplinary", "outcome prediction", "outreach", "pathogen", "predictive modeling", "programs", "protein biomarkers", "recruit", "response", "student training", "synergism", "transmission process", "undergraduate student", "vector", "vector mosquito", "vector transmission", "wild bird" ], "approved": true } }, { "type": "Grant", "id": "12288", "attributes": { "award_id": "1U01NS124961-01A1", "title": "Clinical Trial Readiness for Children 0-5 years with Congenital Muscular Dystrophy Secondary to LAMA2 Mutations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 28184, "first_name": "LINA FERNANDA", "last_name": "Garcia", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-18", "end_date": "2028-08-31", "award_amount": 1295529, "principal_investigator": { "id": 28185, "first_name": "Anne M", "last_name": "Connolly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 879, "ror": "", "name": "RESEARCH INST NATIONWIDE CHILDREN'S HOSP", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal’s overall goal is to hasten drug development for children < 5 years with congenital muscular dystrophy secondary to laminin α2-related dystrophies (LAMA2-RD) mutations. Excellent mouse models of differing severity improved the understanding of pathogenesis in LAMA2-RD. Therapeutic strategies, including protein replacement and apoptosis inhibition (Phase 1), linker gene transfer, and compensatory gene upregulation (pre- clinical proof of concept), are all at various developmental stages but are expected to come to clinical trials in 2-3 years. While all these advances are promising, currently, no validated clinical outcome assessments (COA) are available for children with LAMA2-RD < 5 years. Thus, the need to validate outcome measures and biomarkers is urgent for children (< 5 years) with genetically confirmed LAMA2-RD. Successfully translating any therapy must include these youngest children for whom strength or function-based approaches designed for older “cooperative children” do not work. Clinical trial readiness for infants and young children is particularly critical since therapeutic interventions, if successful, are likely to have the best response when given early. The specific aims of our proposal are to 1) Validate motor function as COA for children with LAMA2-RD, 2) Establish minimal clinically important differences for motor COAs by anchoring them to the clinical global impressions scale, 3) Determine what cohort characteristics will best inform clinical trial eligibility, and 4) Validate novel biomarkers (cross-sectionally measure biceps and rectos femoris by ultrasound) and creatine kinase levels over time. To achieve these aims, we propose a 14-site multicenter prospective 2-year study of 44 children < 5 years at enrollment. Detailed training of at least two clinical evaluators from each collaborating site will take place at the lead institution, Nationwide Children’s Hospital, before enrollment and again in Year 3. We selected the sites based on their expertise in pediatric neuromuscular clinical trials. LAMA2-RD is ultra-rare, and these children are often medically fragile. Therefore, we also selected geographically diverse locations to minimize travel and burden of trial participation. A novel COA developed by necessity during the COVID-19 Pandemic is video assessments of all motor function COAs, further allowing less travel for children. Our partnerships with advocacy groups, including Cure CMD (Congenital Muscular Dystrophy) and the Muscular Dystrophy Association, will allow us to successfully recruit children using a spoke and hub model. The proposal will develop and validate COAs for children < 5 years with LAMA2-RD and will inform future clinical trial design and interpretation. Furthermore, once validated, these COAs are very likely to be successful for children with other rare disorders affecting motor development in early infancy.", "keywords": [ "5 year old", "Address", "Advocacy", "Affect", "Age", "Biological Markers", "Birth", "Blinded", "Breathing", "COVID-19 pandemic", "Capnography", "Carbon Dioxide", "Caregivers", "Certification", "Characteristics", "Chest", "Child", "Child Development", "Childhood", "Clinical", "Clinical Trials", "Clinical Trials Design", "Clustered Regularly Interspaced Short Palindromic Repeats", "Collaborations", "Contracture", "Creatine Kinase", "Data", "Deglutition", "Development", "Diameter", "Disability Evaluation", "Disease Progression", "Duchenne muscular dystrophy", "Eligibility Determination", "Enrollment", "Equipment and supply inventories", "Evaluation", "Exclusion Criteria", "Exhalation", "Future", "Gene Transfer", "Genes", "Geography", "Goals", "Infant", "Inherited", "Inhibition of Apoptosis", "Joints", "Language", "Language Development", "Life", "Location", "Measures", "Medical", "Methods", "Modeling", "Motor", "Multicenter Studies", "Muscle", "Muscle Weakness", "Muscle hypotonia", "Muscular Atrophy", "Muscular Dystrophies", "Mutation", "Neuromuscular Diseases", "Neuromuscular conditions", "Outcome", "Outcome Assessment", "Outcome Measure", "Parents", "Participant", "Pathogenesis", "Pediatric Hospitals", "Persons", "Phase", "Philadelphia", "Proteins", "Quality of life", "Rare Diseases", "Research Personnel", "Respiratory Insufficiency", "Respiratory physiology", "Risk", "Secondary to", "Seizures", "Serum", "Severities", "Site", "Social Development", "Testing", "Therapeutic", "Therapeutic Intervention", "Therapeutic Trials", "Time", "Toddler", "Training", "Translating", "Travel", "United States National Institutes of Health", "Universities", "Up-Regulation", "Validation", "Visit", "Walking", "Washington", "World Health Organization", "age group", "biceps brachii muscle", "biomarker validation", "clinical outcome assessment", "clinical research site", "clinical trial readiness", "cognitive development", "cohort", "congenital muscular dystrophy", "data de-identification", "design", "drug development", "efficacy evaluation", "feeding", "impression", "improved", "inclusion criteria", "infancy", "intervention effect", "laminin alpha 2", "mouse model", "neuromuscular", "novel", "novel marker", "pre-clinical", "preclinical development", "progression marker", "prospective", "rate of change", "recruit", "rectus femoris", "remote assessment", "response", "scoliosis", "treatment strategy", "tria" ], "approved": true } }, { "type": "Grant", "id": "12289", "attributes": { "award_id": "1R15HD112895-01", "title": "Randomized Control Trial of the Co-Parenting for Resilience Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 7137, "first_name": "LAYLA E", "last_name": "ESPOSITO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-18", "end_date": "2026-08-31", "award_amount": 443317, "principal_investigator": { "id": 28186, "first_name": "Ronald Blake", "last_name": "Cox", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1192, "ror": "", "name": "OKLAHOMA STATE UNIVERSITY STILLWATER", "address": "", "city": "", "state": "OK", "zip": "", "country": "United States", "approved": true }, "abstract": "Parental divorce can negatively affect children in ways that are often severe and long lasting. Approximately 25% of the children of divorcing parents have major long-term mental and behavioral health problems compared to approximately only 10% of children in the general population. Even among those who ultimately adjust well, many will experience considerable emotional distress which can lead to maladaptive coping and negative outcomes such as antisocial behavior, depression, school dropout, substance use and precocious sexual activity. In response to the effects of divorce on children, brief prevention interventions focused on teaching parents how to ameliorate the impact of divorce on their children have gained widespread acceptance by court systems across the nation, and online versions of the same have proliferated during COVID-19. However, recent systematic and metanalytic reviews reporting on the efficacy of divorce education programs, while showing promising results, generally lack the methodological rigor to form the strong empirical foundation needed to advance the field in both theory and practice. To address these weaknesses, the current project tests Co-Parenting for Resilience (CPR), a divorce education program that draws on theories from the field of Marriage and Family Therapy and Prevention Science to incorporate empirically-supported therapeutic strategies into a 4-hour psychoeducational workshop. Building upon our previously successful trial using a non- equivalent control group, the proposed study uses a 3-arm (CPR in-person, CPR online, and bibliotherapy attention placebo control) randomized controlled trial with an intent to treat design. The study collects a sample of 300 parents who have recently filed for divorce to accomplish the following three aims: 1) Determine the relative efficacy of the online and in-person versions of CPR to improve child post-divorce adjustment compared to each other and to a bibliotherapy control group at 3- and 12-month follow-ups; 2) Test paths from the online and in-person versions of CPR to child adjustment via parenting competencies; and 3) Identify moderators of the effectiveness of in-person and online formats of CPR such as parent gender, ethnicity, and level and type of conflict between divorcing partners. If accomplished, these aims will provide insight into whether: (a) remitting couples to a divorce education class is more effective than simply reading a book on divorce, (b) in-person or online delivery formats are more beneficial in helping parents overcome the parenting challenges of divorce, and (c) there are subgroups for whom divorce education is more or less effective.", "keywords": [ "10 year old", "Academic Research Enhancement Awards", "Address", "Age", "Alcohols", "Attention", "Behavioral", "Bibliotherapy", "Books", "COVID-19", "Child", "Child Rearing", "Cognition", "Collaborations", "Competence", "Conflict (Psychology)", "Control Groups", "County", "Coupled", "Couples", "Data", "Diagnosis", "Disease remission", "Divorce", "Education", "Educational process of instructing", "Educational workshop", "Effectiveness", "Emotional", "Emotions", "Ethnic Origin", "Exposure to", "Family", "Family Research", "Family psychotherapy", "Foundations", "Gender", "General Population", "Hour", "Individual", "Institution", "Instruction", "Intervention", "Knowledge", "Marriage and Family", "Mediating", "Mediation", "Mental Depression", "Mental Health", "Mental disorders", "Methodology", "Oklahoma", "Outcome", "Parents", "Participant", "Performance", "Persons", "Pharmaceutical Preparations", "Phase", "Pilot Projects", "Placebo Control", "Prevention", "Process", "Program Development", "Program Evaluation", "Proliferating", "Public Health", "Quasi-experiment", "Randomized", "Randomized Controlled Trials", "Reading", "Reporting", "Research", "Research Project Grants", "Rural Population", "Sampling", "School Drop-Outs", "Science", "Sex Behavior", "Stress", "Student Dropouts", "Subgroup", "System", "Testing", "Therapeutic", "antisocial behavior", "arm", "behavior change", "behavioral health", "brief prevention intervention", "coping", "cost", "court", "deep learning", "design", "emotional distress", "experience", "field theory", "follow-up", "graduate student", "improved", "innovation", "insight", "motivational enhancement therapy", "negative affect", "online delivery", "online version", "peer", "physical conditioning", "programs", "psychoeducation", "psychoeducational", "psychoeducational intervention", "resilience", "response", "rural underserved", "social", "substance use", "theories", "undergraduate student" ], "approved": true } }, { "type": "Grant", "id": "12290", "attributes": { "award_id": "1R21MD019396-01", "title": "A Multi-site Investigation of Social Determinants of Health and SARS-CoV-2 Testing and Vaccination Outcomes among Diverse US Latinx Adults", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6121, "first_name": "Priscah", "last_name": "Mujuru", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-21", "end_date": "2025-06-30", "award_amount": 184375, "principal_investigator": { "id": 28187, "first_name": "Elizabeth L", "last_name": "Budd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28188, "first_name": "Stephanie", "last_name": "De Anda", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1156, "ror": "https://ror.org/0293rh119", "name": "University of Oregon", "address": "", "city": "", "state": "OR", "zip": "", "country": "United States", "approved": true }, "abstract": "7. Project Summary Latinxs comprise a large and growing population in the US, but are typically underrepresented in study samples, limiting statistical comparisons to only other racial or ethnic groups.1 Inadequate access to large, diverse samples of Latinxs in public health research has led to treating Latinxs as a monolith, despite known and important within-group differences.1–5 These conditions have led to inadequately tailored disease prevention and control strategies1 and allowed for the persistence of health inequities such as those experienced among Latinxs before and throughout the COVID-19 pandemic compared to non-Latinx Whites8– 12,14 and even to all other racial-ethnic-sex groups.13,92 Yearby's revised Social Determinants of Health (SDOH) Framework explains that structural discrimination (e.g., racism, ethnocentrism, and sexism) is the underlying cause of the inequitable distributions of economic, healthcare access, educational, social, and environmental SDOH across populations, which ultimately results in disproportionate disease burden.19 Individuals hold multiple identities (e.g., ethnic, racial, country of origin, gender, age, language) that interact with structural discrimination in distinct ways,22–24 but how these identities interact with SDOH and SARS-CoV-2 testing and vaccination outcomes within Latinxs is unknown. The present proposal harnesses Latinx-identifying participant data (N = 31,372) from 10 purposively selected, geographically diverse Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) projects to overcome the limitations in prior research. Specifically, using pooled Tier 1 common data elements for Aim 1, we will identify the relative importance of economic, healthcare access, educational, and environmental SDOH on SARS-CoV-2 testing (e.g., engagement in testing, testing access) and vaccination (e.g., vaccination status, reasons to/to not get vaccinated) outcomes within a large, robust individual person data meta-analysis of Latinx US adults. Using the same Tier 1 data for Aim 2, we will investigate how the Aim 1 model varies by race, country of origin, gender, age, and language. Finally, for Aim 3, we will use Tier 2 data and employ scale equating data harmonization techniques to examine additional identity-related moderators (e.g., immigration status), SDOH (e.g., racial discrimination, food insecurity), and more robust measures of testing and vaccination outcomes that advance the Aim 1 and 2 models; and evaluate the degree to which the findings generalize to the national Latinx population. Study findings will advance the empirical knowledge base necessary to design precise, culturally tailored prevention and control strategies within Latinxs to reduce health inequities in COVID-19 and beyond.", "keywords": [ "Address", "Adult", "Age", "Behavior", "COVID-19", "COVID-19 pandemic", "COVID-19 testing", "Common Data Element", "Communities", "Country", "Data", "Discrimination", "Disease", "Economics", "Education", "Equation", "Ethnic Origin", "Ethnic Population", "Gender", "Geography", "Heterogeneity", "Hispanic", "Hospitalization", "Household", "Housing", "Immigration", "Income", "Individual", "Inequity", "Influenza vaccination", "Investigation", "Knowledge", "Language", "Latina", "Latino", "Latinx", "Latinx population", "Lead", "Literature", "Measures", "Medicaid", "Meta-Analysis", "Metadata", "Methods", "Mexico", "Modeling", "Non-Insulin-Dependent Diabetes Mellitus", "Oregon", "Outcome", "Participant", "Persons", "Phase", "Population", "Prevention", "Preventive", "Preventive service", "RADx Underserved Populations", "Race", "Reporting", "Research", "Research Personnel", "SARS-CoV-2 positive", "Sampling", "Sampling Studies", "Sexism", "Site", "Standardization", "Subgroup", "Techniques", "Testing", "United States National Institutes of Health", "Vaccinated", "Vaccination", "barrier to testing", "burden of illness", "data harmonization", "design", "disorder control", "disorder prevention", "experience", "food insecurity", "health care availability", "health disparity", "health equity promotion", "health inequalities", "inequitable distribution", "innovation", "knowledge base", "mortality", "pandemic disease", "public health research", "racial discrimination", "racial population", "racism", "residence", "sex", "social", "social health determinants", "systemic barrier", "testing access", "theories", "uptake", "vaccination outcome" ], "approved": true } }, { "type": "Grant", "id": "12291", "attributes": { "award_id": "272201700061C-P00011-9999-2", "title": "COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-30", "end_date": "2024-09-29", "award_amount": 1830201, "principal_investigator": { "id": 24151, "first_name": "THOMAS", "last_name": "DENNY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The mission of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is to increase basic knowledge of the pathogenesis and transmission of the human immunodeficiency virus (HIV), support the development of therapies for HIV infection and its complications, and support the development of vaccines and other prevention strategies. Reliable laboratory data are essential to the clinical evaluation of candidate HIV vaccine platforms and immunogens. Data from multiple laboratories performing assays in support of single or multiple vaccine candidate trials must be accurate and reproducible. The purpose of the External Quality Assurance Program Oversight Laboratory (EQAPOL) is to provide confidence that individual laboratories generate reliable data to support HIV vaccine immunogen advancement. EQAPOL supports these efforts by participating in the development and availability of validated assays, providing common and well-characterized reagents and Standard Operating Procedures (SOPs), and providing External Quality Assurance (EQA) programs to measure and monitor laboratory performance. This project will provide external quality assurance program support for laboratories performing immunology assays for COVID-19 Prevention Network (CoVPN)-led vaccine efficacy trials.", "keywords": [ "2019-nCoV", "Acquired Immunodeficiency Syndrome", "Antigens", "Binding", "Biological Assay", "Biometry", "COVID-19", "COVID-19 Prevention Network", "COVID-19 assay", "Data", "Development", "Flow Cytometry", "HIV", "HIV Infections", "HIV vaccine", "Immunology", "Immunology procedure", "Individual", "Knowledge", "Laboratories", "Measures", "Mission", "Monitor", "National Institute of Allergy and Infectious Disease", "Pathogenesis", "Performance", "Prevention strategy", "Procedures", "Reagent", "Reproducibility", "SARS-CoV-2 antibody", "Stains", "United States National Institutes of Health", "cytokine", "data management", "data quality", "design", "efficacy trial", "programs", "quality assurance", "repository", "research clinical testing", "therapy development", "transmission process", "vaccine candidate", "vaccine development", "vaccine efficacy", "vaccine platform" ], "approved": true } }, { "type": "Grant", "id": "12292", "attributes": { "award_id": "1R01AR081002-01A1", "title": "Muscle and physical function recovery after acute critical illness", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 28189, "first_name": "MARJORIE JEAN", "last_name": "Lindhurst", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-18", "end_date": "2028-08-31", "award_amount": 450428, "principal_investigator": { "id": 28190, "first_name": "Esther E", "last_name": "Dupont-Versteegden", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1162, "ror": "https://ror.org/02k3smh20", "name": "University of Kentucky", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "Many patients who survive critical illness, including sepsis and acute respiratory failure, have arduous recoveries plagued by an inability to recover muscle and physical function after hospital discharge, resulting in lower quality of life, inability to return to work and disability. The number of patients surviving critical illnesses in the United States continues to rise each year and therefore it is critically important to develop interventions that will support their recovery. Clinical and muscle cellular factors driving skeletal muscle dysfunction are relatively unknown after an acute critical illness, but are necessary to inform intervention development. We will address this knowledge gap by studying myofibrillar and collagen protein turnover, cellular signaling pathways, and markers of damage, inflammation and immune response in the first year of recovery. The unique aspect of this proposal is the serial, intra-patient muscle tissue sampling paired with simultaneously obtained clinical functional parameters over the first year of recovery post hospital discharge. Physical function and quality of life outcomes will be assessed to understand why some patients recover muscle function, yet others develop severe disability. The overall goal of this clinical observational study is to elucidate the cellular environment and the patient’s clinical characteristics contributing to failed muscle recovery and physical disability in survivors of critical illness. Our central hypothesis is that alterations in myofibrillar, mitochondrial and collagen protein homeostasis are underlying muscle and physical dysfunction in patients surviving critical illness. In Aim 1, we will identify trajectory of recovery for muscle strength and power, as well as physical function in patients surviving ICU-related critical illness including pneumonia, sepsis, and COVID-19 etiologies. We hypothesize that patients with a higher initial severity of illness will show poor recovery of muscle strength and physical function during the first year of recovery. In Aim 2, we will determine mechanisms of skeletal muscle deficiencies contributing to disparate recovery in patients surviving ICU-related COVID-19 or other acute lung injury etiologies. We hypothesize that patients with longer ICU durations will show poor recovery of muscle size and increased collagen deposition during the first year of recovery. In addition, we hypothesize that patients with persistent weakness and fatigue have prolonged impairments in mitochondrial function compared to patients who recover their muscle function. Finally, we hypothesize that patients with long-term disability have an inability to recover muscle function due to a cellular environment of that is not permissive to a positive protein balance. We will use stable isotope mass spectroscopy measurements of muscle biopsies to determine synthesis of myofibrillar, mitochondrial and collagen protein. Findings from this study, will inform why some patients develop persistent disability and others gradually improve. The results from this research will guide future development of therapeutic interventions that are specific to skeletal muscle deficits with consideration for patient related factors such as age and co-morbid burden.", "keywords": [ "Acceleration", "Acute", "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Acute respiratory failure", "Adult", "Age", "Area", "Attention", "Automobile Driving", "Awareness", "Biopsy", "COVID-19", "Cells", "Characteristics", "Clinical", "Collagen", "Communities", "Critical Illness", "Data", "Deposition", "Deuterium Oxide", "Development", "Disabled Persons", "Disparate", "Environment", "Equilibrium", "Etiology", "Extracellular Matrix", "Fatigue", "Fibrosis", "Functional disorder", "Future", "Goals", "Growth", "Hospitalization", "Hospitals", "Immune", "Immune response", "Impairment", "Inflammation", "Inflammatory", "Influenza", "Intensive Care Units", "Intervention", "Knowledge", "Label", "Mass Spectrum Analysis", "Measurement", "Measures", "Metabolic", "Mission", "Mitochondria", "Muscle", "Muscle Fibers", "Muscle Weakness", "Muscle function", "Muscle satellite cell", "National Institute of Arthritis and Musculoskeletal and Skin Diseases", "Observational Study", "Outcome", "Patients", "Pattern", "Pharmacological Treatment", "Phenotype", "Physical Function", "Pneumonia", "Proteins", "Quality of life", "Recovery", "Recovery of Function", "Rehabilitation therapy", "Research", "Research Project Grants", "Respiration", "Sepsis", "Severity of illness", "Signal Pathway", "Skeletal Muscle", "Survivors", "Therapeutic Intervention", "Time", "Tissue Sample", "Tissues", "United States", "Work", "comorbidity", "disability", "evidence base", "improved", "interest", "muscle strength", "nutrition", "participant enrollment", "patient subsets", "pharmacologic", "physically handicapped", "predictive modeling", "protein biomarkers", "protein degradation", "proteostasis", "response", "sepsis induced ARDS", "skeletal muscle wasting", "stable isotope", "therapeutic development", "therapy development" ], "approved": true } }, { "type": "Grant", "id": "12293", "attributes": { "award_id": "1R43AI174350-01A1", "title": "Preclinical development of a Nipah Virus inhibitor", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 10523, "first_name": "Mindy I.", "last_name": "Davis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-15", "end_date": "2024-08-31", "award_amount": 295096, "principal_investigator": { "id": 28191, "first_name": "SEAN", "last_name": "EKINS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2081, "ror": "", "name": "COLLABORATIONS PHARMACEUTICALS, INC.", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2 has led to an increased urgency to develop treatments for additional emerging viruses and potentially provide broader spectrum antivirals in order to anticipate pandemic viruses. Nipah virus (NiV) is a bat-borne pathogen (family Paramyxoviridae) that results in acute and often fatal (recent outbreaks in India have demonstrated case fatality ~70%) respiratory and neurological disease for which there is currently no FDA approved treatment. There have been very few small molecule antivirals that have demonstrated activity against NiV either in vitro or in vivo. These include favipiravir (EC90 15.87- 123.8 µM) which resulted in survival in the hamster model and remdesivir (EC90 50-100 nM) when dosed daily by the intravenous (IV) route in the African green monkey (AGM) model resulting in their survival. We recently identified the antiviral activity of pyronaridine (EC50 = 65.57 nM and CC50 3.65 µM) for NiV (Malaysia strain, Patent No. 17/092,058). We have also shown that pyronaridine has efficacy against Ebola in vitro and efficacy in vivo in mice and guinea pig. Additionally, pyronaridine has demonstrated promising activity in vitro against Marburg virus and in vivo efficacy against SARS-CoV-2 in mice. We have recently shown that pyronaridine is lysosomotropic and binds to the Ebola glycoprotein as well as decreases the inflammatory cytokine storm in mice induced by SARS-CoV-2. We now propose to assess the oral maximum tolerated dose and pharmacokinetics prior to performing efficacy studies in the hamster model of NiV. If we are successful in demonstrating in vivo efficacy, we will file an orphan drug designation and a preIND with the FDA. If we demonstrate statistically significant efficacy in Phase I we will then perform efficacy testing in Phase II using the African Green Monkey model for NiV, perform IND enabling toxicology studies and manufacture GMP grade pyronaridine tertraphosphate. Our ultimate aim is to bring a treatment to market for NiV which can be stockpiled by the USA and other countries in preparation for future outbreaks.", "keywords": [ "2019-nCoV", "Acute", "African Green Monkey", "Animals", "Anti-Infective Agents", "Antimalarials", "Antiviral Agents", "Binding", "Blood", "Body Weight", "Body Weight decreased", "Cavia", "Cessation of life", "Combined Modality Therapy", "Country", "Data", "Democratic Republic of the Congo", "Disease", "Disease Outbreaks", "Dose", "Drug Kinetics", "Ebola", "Ebola virus", "FDA approved", "Family", "Feedback", "Future", "Glycoproteins", "Goals", "Government", "Hamsters", "Human", "In Vitro", "India", "Infection", "Inflammatory", "Injections", "Intellectual Property", "Intravenous", "Investments", "Legal patent", "Malaysia", "Marburgvirus", "Marketing", "Maximum Tolerated Dose", "Modeling", "Monitor", "Morbidity - disease rate", "Mus", "Nipah Virus", "Oral", "Orphan Drugs", "Paramyxovirus", "Pharmaceutical Preparations", "Pharmacologic Substance", "Phase", "Preparation", "Privatization", "Respiratory Disease", "Route", "SARS-CoV-2 inhibitor", "Science", "Sodium Chloride", "Taxes", "Testing", "Time", "Tissues", "Toxicology", "Viral", "Viral Physiology", "Virus", "Virus Inhibitors", "Virus Replication", "Water", "Work", "bat-borne", "clinical development", "coronavirus disease", "cytokine release syndrome", "efficacy evaluation", "efficacy study", "efficacy testing", "future outbreak", "in vitro activity", "in vivo", "inhibitor", "intraperitoneal", "manufacture", "meter", "nervous system disorder", "nonhuman primate", "novel", "pandemic virus", "pathogen", "preclinical development", "preclinical study", "pyronaridine", "remdesivir", "small molecule" ], "approved": true } }, { "type": "Grant", "id": "12294", "attributes": { "award_id": "3UM1DA049415-04S1", "title": "CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York State", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 20583, "first_name": "KEISHER S", "last_name": "Highsmith", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-15", "end_date": "2024-03-31", "award_amount": 833008, "principal_investigator": { "id": 28192, "first_name": "Nabila", "last_name": "El-Bassel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28193, "first_name": "Louisa", "last_name": "Gilbert", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 922, "ror": "", "name": "COLUMBIA UNIV NEW YORK MORNINGSIDE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This supplement aims to explore the impact of the infusion of health equity principles on overdose prevention strategies during the implementation of the Communities That Heal (CTH) intervention as part of the HEALing Communities Study (HCS). The HCS is a multi-site, parallel arm, cluster randomized, wait-list controlled trial evaluating the impacts of the CTH intervention, compared with usual care in wait-list communities, on overdose deaths. The overall goal of the HCS is to reduce opioid overdose deaths by 40% in 67 HCS communities across four states. Communities form coalitions to make shared decisions about what overdose prevention strategies to implement and how best to implement them, particularly strategies that promote Overdose Prevention Education and Naloxone Distribution (OEND) and Medications for Opioid Use Disorder (MOUD). Even though minoritized communities (whether due to race, ethnicity, gender, or LGBTQIA+ status) have less and poorer access to treatment for Opioid Use Disorder (OUD) and associated disparities in outcomes at its outset, HCS did not explicitly aim to reduce disparities or measure the effect of centering equity on overdose prevention. This approach changed in 2020 with an acute awareness of the racial and ethnic disparities within the COVID epidemic and the racial awakening in response to the George Floyd killing. This supplement will leverage its parent study existing staff and infrastructure and study staff to analyze surveys and other qualitative data already collected. The primary data sources will include surveys of coalition members, completed at four-time points during the study period; the Opioid-Overdose Reduction Continuum of Care Approach Tracker (ORCCAT), completed monthly by study staff, that includes overdose prevention information by strategy, sector, venue, population served, coalition approval date, implementation plan developed, date started, number of partners/practices associated with strategy, and mode of delivery; and REACH data, completed by study staff monthly once each strategy is implemented that includes information on number of persons reached and demographics of those reached (e.g., race, ethnicity, sex, age). Data analysis will consist of qualitative analysis looking at associations between survey answers regarding health equity topics and incorporation of equity into strategies, and qualitative analysis examining how coalitions discussed and prioritized equity topics. The parent study’s PRISM/RE-AIM(S) conceptual framework will guide this study with a novel health equity lens to examine how diversifying coalitions and infusing opioid overdose prevention strategies with health equity principles may help reach minoritized communities and how these contextual factors and processes may interact to promote or impede health equity. Results from this study may be used to inform policies, strategies, and practices for incorporating health equity principles when implementing overdose prevention strategies.", "keywords": [ "Achievement", "Acute", "Address", "Adoption", "Age", "Attention", "Awareness", "Black Populations", "COVID-19 pandemic", "Communities", "Continuity of Patient Care", "County", "Data", "Data Analyses", "Data Sources", "Death Rate", "Decision Making", "Discrimination", "Disparity", "Drug usage", "Equity", "Ethnic Origin", "Frequencies", "Gender", "Geography", "Goals", "Grant", "Health", "Health Services Accessibility", "Homelessness", "Housing", "Individual", "Infrastructure", "Infusion procedures", "Intervention", "Kentucky", "Learning", "Legal system", "Manuscripts", "Maps", "Massachusetts", "Measures", "Modeling", "Naloxone", "Nature", "New York", "Not Hispanic or Latino", "Ohio", "Outcome", "Outcome Study", "Overdose", "Overdose reduction", "Parents", "Participant", "Pattern", "Persons", "Pharmaceutical Preparations", "Phase", "Policies", "Population", "Prevention education", "Prevention strategy", "Process", "Protocols documentation", "Public Health", "Publications", "Publishing", "Race", "Racial Equity", "Randomized", "Reach Effectiveness Adoption Implementation and Maintenance", "Readiness", "Reporting", "Research Personnel", "Resources", "Respondent", "Rural", "Site", "Special Population", "Surveys", "Time", "Training", "Transportation", "Underserved Population", "Waiting Lists", "Work", "arm", "black men", "comparative effectiveness", "contextual factors", "demographics", "design", "disparity reduction", "dynamic system", "effectiveness evaluation", "ethnic disparity", "ethnic diversity", "ethnic minority", "ethnic minority population", "healing", "health care availability", "health equity", "implementation strategy", "innovation", "medication for opioid use disorder", "meetings", "member", "minority communities", "novel", "opioid epidemic", "opioid mortality", "opioid overdose", "opioid use disorder", "overdose death", "overdose prevention", "peer influence", "peer networks", "racial disparity", "racial minority", "racial minority population", "response", "satisfaction", "sex", "shared decision making", "social health determinants", "social stigma", "sociodemographics", "tool", "treatment as usual", "trend" ], "approved": true } }, { "type": "Grant", "id": "12295", "attributes": { "award_id": "1R03CA280302-01", "title": "Tumor downstaging with small molecule therapeutics to enhance Uveal Melanoma metastasis eradication by B7-H3 CAR T cells", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21448, "first_name": "CONNIE L", "last_name": "Sommers", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-20", "end_date": "2025-08-31", "award_amount": 167000, "principal_investigator": { "id": 28194, "first_name": "Cristina R.", "last_name": "Ferrone", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 766, "ror": "https://ror.org/02pammg90", "name": "Cedars-Sinai Medical Center", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Uveal Melanoma (UM) is a rare cancer with an incidence of 5 cases per million in the United States. Nearly half UM patients develop isolated liver metastases due to the high tendency of UM cells to spread to the liver. No cure has been found for patients with metastatic UM (mUM). Tebentafusp, is the only FDA-approved therapy for mUM. However, it has shown modest improvements in terms of overall response and progression-free survival and its applicability is limited to only 40% of mUM patients. The lack of effective treatment options for mUM has prompted us to design a novel combinatorial immunotherapeutic strategy based on the use of Chimeric Antigen Receptor (CAR) T cells specifically redirected against B7-H3. The latter has been selected as the target of our immunotherapeutic strategy, since it is highly expressed on UM cell lines and mUM tumor tissue samples, but has a limited expression on normal tissues. It is a general experience that CAR T cell-based immunotherapy is not effective in eradicating solid tumors both in preclinical and clinical investigations. This result is likely caused by multiple mechanisms, among which the major role is played by their use in hosts with high tumor load; the resulting unfavorable effector to target (E:T) ratio in the tumor microenvironment has a negative impact on the antitumor activity of CAR T cells, as indicated by the results generated by preclinical and clinical investigations. The information in the literature and our preliminary results have provided the rationale to design a strategy which applies first a tumor debulking approach to reduce tumor load and then CAR T cell- based immunotherapy to eradicate UM metastases. We will use the combination of trametinib, a mitogen-activated protein kinase kinase inhibitor (MEKi) and of panobinostat, a histone deacetylase inhibitor (HDACi), since this combination has been shown to induce marked regression of UM liver metastases in mice. Furthermore, this combination does not affect B7- H3 expression by UM cells and the antitumor activity of B7-H3 CAR T cells. Therefore, after having shown that B7-H3 CAR T cells can recognize and eliminate UM cells surviving the treatment with the MEKi and HDACi combination, we will investigate whether tumor debulking induced by the MEKi and HDACi combination can enhance the ability of B7-H3 CAR T cells to eradicate UM liver metastases in NSG mice. Since one major limitation of CAR T cell-based therapy is represented by its potential toxicity and/or cytokine release syndrome, we have incorporated in our CAR construct an inducible caspase 9 safety switch which allows rapid elimination of CAR T cells in case of unexpected toxicities. If the results generated by our experiments are positive, they will have a major impact on the treatment of mUM.", "keywords": [ "Affinity", "Awareness", "CAR T cell therapy", "CASP9 gene", "CD276 gene", "Cell Line", "Cell Survival", "Cells", "Cellular immunotherapy", "Clinical", "Collaborations", "Complex", "Cytolysis", "Data", "Diagnosis", "Disease", "FDA approved", "Generations", "Goals", "HDAC4 gene", "HLA-A2 Antigen", "Histone Deacetylase Inhibitor", "Human", "Immunotherapeutic agent", "Immunotherapy", "In Vitro", "Incidence", "Investigation", "Label", "Literature", "Liver", "MEKs", "Mediating", "Melanoma Cell", "Metastatic Neoplasm to the Liver", "Methodology", "Mitogen-Activated Protein Kinase Kinases", "Monitor", "Mus", "Neoplasm Metastasis", "Normal Cell", "Normal tissue morphology", "Operative Surgical Procedures", "Patients", "Play", "Predisposition", "Progression-Free Survivals", "Proteins", "Residual state", "Role", "SILV gene", "Safety", "Solid Neoplasm", "Specificity", "T cell therapy", "T-Cell Receptor", "T-Lymphocyte", "Testing", "Time", "Tissue Sample", "Toxic effect", "Translating", "Tumor Antigens", "Tumor Burden", "Tumor Debulking", "Tumor Tissue", "Tumor Volume", "United States", "Uveal Melanoma", "bioluminescence imaging", "cancer cell", "chimeric antigen receptor", "chimeric antigen receptor T cells", "clinical investigation", "combinatorial", "cytokine release syndrome", "cytotoxic", "design", "effective therapy", "expectation", "experience", "experimental study", "gp100 Antigen", "improved", "in vivo", "inhibitor", "kinase inhibitor", "mortality", "mouse model", "novel", "pre-clinical", "rare cancer", "response", "small molecule therapeutics", "tumor", "tumor growth", "tumor microenvironment" ], "approved": true } } ], "meta": { "pagination": { "page": 1383, "pages": 1421, "count": 14209 } } }